Home / Market News / $SMMT
fiscal.ai Corporate Catalyst Impact 65/100 ● negative

Bernstein Downgrades Summit Therapeutics to Underperform

Nov 18, 2026, 7:07 PM UTC · Primary ticker $SMMT

Bernstein downgraded Summit Therapeutics to 'Underperform' from 'Market Perform' with a new price target of $8.30. This analyst action is a negative signal for the company, contrasting with its current average 'overweight' rating and higher mean price target from other analysts.

Bernstein downgraded Summit Therapeutics to 'Underperform' from 'Market Perform' and set a price target of $8.30. This move is significant because it represents a bearish outlook from a major investment bank, directly contradicting the current average 'overweight' rating and much higher mean price target of $29.06 from other analysts. This divergence in analyst opinion could create volatility for SMMT stock in the short term as investors weigh Bernstein's new stance against existing sentiment. For traders, this presents a potential short-term selling opportunity or a long-term buying opportunity if they believe Bernstein's downgrade is an overreaction or if the company's clinical programs show positive developments that could lead to a re-rating.

$SMMT negative Analyst downgrade
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.